Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

The FDA has granted 510(k) clearance to Cutera Inc's (NASDAQ:CUTR) AviClear for acne. The Company notes that AviClear is the first and only energy-based device to receive this designation to treat mild, moderate, and severe acne. AviClear is a laser treatment that offers a safe, prescription-free solution for acne. In addition to reducing existing acne,…

Benzinga

FDA Pushes Bristol Myers' Reblozyl Decision Date In Non-Transfusion Dependent Beta Thalassemia

The

Benzinga

Drugs that treat opioid use disorder are a good use for multibillion-dollar settlement funds

States, cities, counties and tribal governments across the nation will soon receive a windfall through several major opioid settlements. Drug distributors and manufacturers, including Purdue Pharma and the Sackler family members who own it, will relinquish a total of about US$32 billion for their role in the overdose crisis. Other…

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

34 Stocks Moving in Friday's Pre-Market Session

Gainers Clever Leaves Holdings Inc. (NASDAQ: CLVR) rose 40.5% to $2.22 in pre-market trading after the company reported better-than-expected Q4 sales results and reaffirmed FY22 guidance.

Benzinga

Why MEI Pharma Stock Is Plummeting After Hours

MEI Pharma Inc (NASDAQ: MEIP) shares are plunging in Thursday's after-hours session after the company provided an investor update following a recent meeting with the U.S. Food and Drug Administration.

Benzinga

Google Submits Fitbit's Passive Heart Rate Monitoring Feature For FDA Approval

Alphabet Inc (NASDAQ: GOOG) has submitted data to the FDA

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Hawaii Passes And Amends Two Measures To Form Psilocybin Working Group, Move Research Forward

In Hawaii, senators approved two identical measures to form a psilocybin working group, Marijuana Moment reported. The goal of the group would be to explore the therapeutic potential of the psychedelic, but the resolutions were amended and patient access will be contingent on federal approval of psilocybin. Both proposals —sponsored by…

Benzinga

Five Companies Developing Second Generation Psychedelics For Mental Health

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics molecules, these upgraded compounds could offer improved therapeutic profiles with reduced side effects. For some companies in the psychedelics space, second generation psychedelics could be the key to success in an increasingly…

Benzinga

FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting

The

Benzinga

FDA reviews ALS drug after lobbying by patients, politicians

The Food and Drug Administration meets next week to review a closely watched drug for ALS, or Lou Gehrig’s disease, following months of lobbying by patient groups and congressional lawmakers

The Independent UK

FDA advisory panel to discuss additional Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK

Pfizer's RSV Vaccine Candidate Receives FDA Breakthrough Therapy Tag For Prevention of RSV In Older Adults

The FDA has granted Breakthrough Therapy Designation to Pfizer Inc's (NYSE:PFE) respiratory syncytial virus (RSV) vaccine candidate (PF-06928316 or RSVpreF) to prevent lower respiratory tract disease caused by RSV in 60 years of age or older. The positive results primarily inform the FDA decision of Phase 2a study evaluating the safety, immunogenicity, and efficacy…

Benzinga

FDA Approves Novartis' Pluvicto As First Targeted Radioligand Therapy For Prostate Cancer

The FDA approved Novartis AG's (NYSE:NVS) Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat patients with a type of advanced prostate cancer that has spread to other parts of the body. Pluvicto is a targeted radioligand therapy for adult patients who have already undergone other anticancer treatments. The company said it had submitted…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Quest Diagnostics Secures CDC Contract To Support COVID-19 Research

The Centers for Disease Control and Prevention (CDC) has granted a contract to Quest Diagnostics Inc (NYSE:DGX) to perform testing and provide laboratory data analysis to help identify patterns in SARS-COV-2 seroprevalence on a multistate basis. Quest was awarded the contract following a competitive bid. The total contract value with all options is valued…

Benzinga

Celcuity Plans To Start Pivotal Gedatolisib Trial In Breast Cancer In 1H 2022

Celcuity Inc (NASDAQ:CELC) concluded two formal meetings with the FDA to obtain their feedback on the gedatolisib Phase 3 trial in the breast cancer setting. The study dubbed VIKTORIA-1 will evaluate gedatolisib combined with fulvestrant with or without palbociclib in HR+/HER2- advanced breast cancer. The trial will include adult patients whose disease has…

Benzinga

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL

Here's a roundup of top developments in the biotech space over the last 24 hours:

Asharq Al-Awsat

Moderna Says Infant Covid Vaccine Succeeded in Trial

US biotech firm Moderna on Wednesday said it was pursuing regulatory approval for its Covid vaccine in children under six years old after the two-shot regimen was found to be safe and produced a strong immune response. Specifically, two doses of 25 micrograms given to babies, toddlers and preschoolers generated…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Biden Administration Contemplating Second COVID-19 Booster Shot Recommendation Within Weeks: Politico

The Biden administration could authorize a fourth dose or second COVID-19 booster shot for people aged 65 years and above within weeks, amid rising concern over a potential resurgence of cases,

Benzinga

DFFN: Additional Tissue Oxygenation Trial Results Expected Mid-2022…

By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT

The Independent UK

EXPLAINER: What to know about COVID vaccines for little kids

Moderna says it will ask regulators to authorize its COVID-19 vaccine for children under 6 but several hurdles need to be cleared before the shots could become available

Benzinga

LifeMine Therapeutics, GSK Ink $70M Drug Discovery, Development Pact

LifeMine Therapeutics Inc, a drug discovery startup that uses genetically-encoded small molecules, has partnered with GlaxoSmithKline plc (NYSE:GSK) to discover and develop drugs from fungal genomes. GSK will bring three targets for LifeMine to run through its proprietary drug discovery platform, which scans for fungi that could be a match to create a…

Benzinga

Moderna's COVID-19 Vaccine Shows Neutralizing Antibody Response In Kids Under 6

Moderna Inc (NASDAQ:MRNA) has announced interim data from the Phase 2/3 KidCOVE study of its COVID-19 vaccine (mRNA-1273) in children six months to under six years. The interim analysis showed that two 25 μg doses of mRNA-1273 in participants 6 months to under six years met the primary endpoint with robust neutralizing antibody…

Tribune News Service

Moderna to seek emergency authorization for COVID-19 vaccine use for kids under 6

Kids, prep those arms.

Benzinga

Novavax's COVID-19 Vaccine Scores Green Light In India with First Approval For Adolescents

Novavax Inc's (NASDAQ:NVAX) COVID-19 vaccine has got emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years. The authorization is a global first approval in adolescents for the vaccine manufactured and marketed in India by the Serum Institute of India under the brand name Covovax. Novavax said…

1 … 230 231 232 233

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

337 stories

LLY

320 stories

Centers for Disease Control and Prevention

314 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.